{"denoms":[{"counts":[{"groupId":"BG000","value":"68"}],"units":"Participants"}],"groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"BG000","title":"Zanubrutinib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.41","value":"67.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"36"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"58"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Multiple"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Not Reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}